Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
US5641749A · kind A · utility
60Cited by
21References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 29, 1995 |
| Grant date | Jun 24, 1997 |
| Priority date | — |
| Expiry date | Nov 29, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P27/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates generally to methods for treating injury or degeneration of retinal ganglion cells by administering glial cell line-derived neurotrophic factor (GDNF). The invention relates specifically to methods for treating optic nerve injury or degeneration associated with glaucoma.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.